Kite, a Gilead Company , today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous ...

Emma Heming Willis watched her husband Bruce retreat into silence, their once lively conversations dissolving into frustration. For years, she wondered if their 16-year marriage was falling apart, ...

The Primary Progressive Aphasia (PPA) Program provides individual and group treatment for clients who who are experiencing a decline in communication abilities consistent with PPA. This program ...

Frontotemporal dementia is a progressive neurological disorder that affects the frontal and temporal lobes of the brain. These areas are crucial for behavior, language, and emotional regulation.

“Subtle signs of delirium and/or declining mental awareness can include disorientation about date, location, reason for admission,” said Meghana R. Medavaram, MD, associate director of consultation ...

AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...

Evaluating quality of life (QOL) in patients with idiopathic pulmonary fibrosis (IPF) goes beyond lung function numbers. It also shows how treatments affect daily well-being and guides funding, ...

Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, ...

In older people with dementia, not recognising others is not uncommon – it eventually happens to everyone with Alzheimer’s disease. In early-onset dementias that affect the right side of the brain, it ...

MarketWatch Guides may receive compensation from companies that appear on this page. The compensation may impact how, where and in what order products appear, but it does not influence the ...